Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
Metastatic Colorectal Cancer
DRUG: Nexavar (Sorafenib) and irinotecan (Campto)
disease control, 6 months
Assessment of adverse events by using the NCI-CTCAE version 3 scale, 6 months|progression free survival, 24 months|overall survival, 36 months
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.